Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $253.8MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Rhodes Jason P | Director | Aug 14 '26 | Sale | $25.00 | 2,160,516 | $54,012,900 | 428,946 | Aug 17 05:30 PM |
| Rhodes Jason P | Director | Aug 13 '26 | Sale | $26.20 | 426,412 | $11,171,994 | 751,411 | Aug 17 05:30 PM |
| Friedl-naderer Johanna | Chief Commercial Officer | Aug 13 '26 | Sale | $26.28 | 226 | $5,939 | 153,982 | Aug 17 04:08 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.